Industry Should Prefer Early Collaboration "Agreement" Meetings - Alpert
This article was originally published in The Gray Sheet
Executive Summary
FDA's propensity to suggest that sponsors hold non-binding "agreement" meetings in lieu of binding "determination" meetings in their pursuit of agency go-ahead is in industry's best interest, Susan Alpert, director of the Center for Devices and Radiological Health's Office of Device Evaluation, maintained.